{"id":"abp-501","safety":{"commonSideEffects":[{"rate":"10–20%","effect":"Injection site reactions"},{"rate":"15–25%","effect":"Upper respiratory tract infections"},{"rate":"5–10%","effect":"Headache"},{"rate":"1–3%","effect":"Serious infections"},{"rate":"<1%","effect":"Tuberculosis reactivation"}]},"_chembl":{"chemblId":"CHEMBL228196","moleculeType":"Small molecule","molecularWeight":"246.33"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ABP 501 is a monoclonal antibody that binds to and neutralizes TNF-α, a key inflammatory cytokine. By inhibiting TNF-α signaling, it suppresses the inflammatory cascade involved in autoimmune and inflammatory diseases. This mechanism is identical to the reference biologic adalimumab (Humira).","oneSentence":"ABP 501 is a biosimilar of adalimumab that blocks tumor necrosis factor-alpha (TNF-α) to reduce inflammation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:58:35.679Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Crohn's disease"},{"name":"Ulcerative colitis"},{"name":"Ankylosing spondylitis"},{"name":"Psoriatic arthritis"},{"name":"Psoriasis"}]},"trialDetails":[{"nctId":"NCT02160015","phase":"PHASE1","title":"Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-05-20","conditions":"Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia","enrollment":12},{"nctId":"NCT07495644","phase":"","title":"Efficacy of Different Biological Treatments in Patients With Inflammatory Bowel Disease After One Year of Treatment in Upper Egypt","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-03-01","conditions":"Inflamatory Bowel Disease (Crohn&#39;s and Ulcerative Colitis)","enrollment":95},{"nctId":"NCT01856192","phase":"PHASE2","title":"Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-08-27","conditions":"Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma","enrollment":349},{"nctId":"NCT06926478","phase":"PHASE1","title":"Subconjunctival Humira for Boston Keratoprosthesis","status":"NOT_YET_RECRUITING","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2026-06-01","conditions":"Penetrating Keratoplasty, Multiple Graft Failure, Ocular Cicatricial Pemphigoid","enrollment":8},{"nctId":"NCT01829568","phase":"PHASE1","title":"Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-06-26","conditions":"Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma","enrollment":33},{"nctId":"NCT04609046","phase":"PHASE1","title":"Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-24","conditions":"Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System","enrollment":47},{"nctId":"NCT07491913","phase":"NA","title":"Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission","status":"RECRUITING","sponsor":"Marmara University","startDate":"2025-06-15","conditions":"Takayasu Arteritis","enrollment":40},{"nctId":"NCT07348588","phase":"PHASE1, PHASE2","title":"Intravitreal Adalimumab in Inherited and Degenerative Retinal Diseases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centro de Pesquisa Rubens Siqueira","startDate":"2024-03-01","conditions":"Retinitis Pigmentosa (RP), Extensive Macular Atrophy With Pseudodrusen (EMAP)","enrollment":30},{"nctId":"NCT06654882","phase":"PHASE3","title":"Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis","status":"RECRUITING","sponsor":"Duke University","startDate":"2026-01-09","conditions":"Polyarticular Course Juvenile Idiopathic Arthritis (JIA)","enrollment":400},{"nctId":"NCT02840175","phase":"PHASE3","title":"Treatment Tapering in JIA With Inactive Disease","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-05-18","conditions":"Juvenile Idiopathic Arthritis","enrollment":62},{"nctId":"NCT07486843","phase":"PHASE4","title":"Preventing Structural Damage in Early Psoriatic Arthritis","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2026-03-16","conditions":"Psoriatic Arthritis (PsA)","enrollment":108},{"nctId":"NCT05025800","phase":"PHASE1, PHASE2","title":"ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-10-13","conditions":"Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma","enrollment":47},{"nctId":"NCT04527380","phase":"PHASE3","title":"A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2021-04-13","conditions":"Juvenile Psoriatic Arthritis, Enthesitis Related Arthritis","enrollment":101},{"nctId":"NCT06045754","phase":"PHASE4","title":"A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease","status":"RECRUITING","sponsor":"Takeda","startDate":"2024-04-18","conditions":"Crohn's Disease","enrollment":100},{"nctId":"NCT05913817","phase":"","title":"The Evaluation of Injection Site Pain and Adherence in Patients Switching From a Low To High Concentration Adalimumab (AVT-02) Across Multiple Indications.","status":"COMPLETED","sponsor":"Jamp Pharma Corporation","startDate":"2023-01-09","conditions":"Crohn Disease, Ulcerative Colitis, Rheumatoid Arthritis","enrollment":324},{"nctId":"NCT04870203","phase":"PHASE3","title":"Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Bordeaux","startDate":"2021-07-15","conditions":"Rheumatoid Arthritis","enrollment":160},{"nctId":"NCT07061574","phase":"PHASE1, PHASE2","title":"A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-03-30","conditions":"Type 1 Diabetes, New Onset","enrollment":120},{"nctId":"NCT05803187","phase":"","title":"Clinical Study of Stage IV Psoriasis in Children With Geleli","status":"COMPLETED","sponsor":"Bio-Thera Solutions","startDate":"2023-04-05","conditions":"Plaque Psoriasis","enrollment":80},{"nctId":"NCT04372108","phase":"","title":"A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis","status":"RECRUITING","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2021-06-24","conditions":"Crohn Disease, Colitis, Ulcerative","enrollment":1056},{"nctId":"NCT00508547","phase":"","title":"Psoriasis Longitudinal Assessment and Registry","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2007-06-21","conditions":"Psoriasis","enrollment":15842},{"nctId":"NCT06996652","phase":"PHASE2","title":"An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)","status":"NOT_YET_RECRUITING","sponsor":"Yale University","startDate":"2026-04","conditions":"REM Sleep Behavior Disorder","enrollment":108},{"nctId":"NCT02446457","phase":"PHASE2","title":"Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-07-31","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma","enrollment":53},{"nctId":"NCT06037811","phase":"PHASE2","title":"Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis","status":"RECRUITING","sponsor":"Tom Appleton","startDate":"2024-04-15","conditions":"Inflammatory Arthritis, Immune-related Adverse Event","enrollment":30},{"nctId":"NCT07423533","phase":"PHASE2","title":"Phase IIb Clinical Study to Assess the Efficacy and Safety of GenSci120 Injection in Patients With Moderately to Severely Active RA Who Have an Inadequate Response to at Least One DMARD","status":"NOT_YET_RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2026-02","conditions":"Rheumatoid Arthritis","enrollment":450},{"nctId":"NCT06016517","phase":"","title":"Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis","status":"NOT_YET_RECRUITING","sponsor":"Tufts Medical Center","startDate":"2026-03-15","conditions":"Arthritis, Rheumatoid","enrollment":18},{"nctId":"NCT06100744","phase":"PHASE3","title":"A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab","status":"RECRUITING","sponsor":"AbbVie","startDate":"2024-07-08","conditions":"Juvenile Psoriatic Arthritis","enrollment":40},{"nctId":"NCT07177209","phase":"","title":"Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population","status":"NOT_YET_RECRUITING","sponsor":"Pfizer","startDate":"2026-02-27","conditions":"Ulcerative Colitis","enrollment":4000},{"nctId":"NCT07398651","phase":"NA","title":"Apremilast and Adalimumab in Psoriatic Arthritis Patients","status":"NOT_YET_RECRUITING","sponsor":"Tanta University","startDate":"2026-12-30","conditions":"Psoriatic Arthritis, Ultrasound Assessment, TNF","enrollment":60},{"nctId":"NCT06440629","phase":"PHASE4","title":"Effect of Proactive Therapeutic Drug Monitoring on Maintenance of Sustained Disease Control in Adults With Rheumatoid Arthritis on a Subcutaneous TNF Inhibitor: The Rheumatoid Arthritis Therapeutic DRUg Monitoring Trial (RA-DRUM)","status":"RECRUITING","sponsor":"Diakonhjemmet Hospital","startDate":"2024-08-20","conditions":"Rheumatoid Arthritis","enrollment":350},{"nctId":"NCT07388446","phase":"NA","title":"MAIT Cells in Hidradenitis Suppurativa","status":"NOT_YET_RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2026-02-01","conditions":"Hidradenitis Suppurativa (HS)","enrollment":45},{"nctId":"NCT06941376","phase":"PHASE2","title":"An Open-Label Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2025-08-01","conditions":"Relapsing Polychondritis","enrollment":20},{"nctId":"NCT05305066","phase":"NA","title":"Stand UP to Rheumatoid Arthritis (SUPRA)","status":"RECRUITING","sponsor":"Marie Hudson, MD","startDate":"2023-02-01","conditions":"Rheumatoid Arthritis","enrollment":75},{"nctId":"NCT03153319","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","startDate":"2017-06-05","conditions":"Mucopolysaccharidosis I, Mucopolysaccharidosis II, Mucopolysaccharidosis VI","enrollment":14},{"nctId":"NCT07147257","phase":"PHASE1","title":"A Trial to Assess the Pharmacokinetic Similarity Between CHS-1420 40 mg/0.4 mL and HUMIRA® (Adalimumab) 40 mg/0.4 mL in Healthy Chinese Adult Participants Under Fasting Conditions","status":"COMPLETED","sponsor":"Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.","startDate":"2025-02-12","conditions":"Healthy Participants","enrollment":238},{"nctId":"NCT03412747","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2018-01-26","conditions":"Chronic Plaque Psoriasis, Moderate to Severe Plaque Psoriasis","enrollment":478},{"nctId":"NCT03895203","phase":"PHASE3","title":"A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2019-04-03","conditions":"Psoriatic Arthritis","enrollment":852},{"nctId":"NCT04259138","phase":"PHASE4","title":"Determination of the Optimal Treatment Target in Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alimentiv Inc.","startDate":"2020-02-18","conditions":"Colitis, Ulcerative","enrollment":672},{"nctId":"NCT01000441","phase":"PHASE4","title":"Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis","status":"COMPLETED","sponsor":"University Hospital, Strasbourg, France","startDate":"2009-12-23","conditions":"Rheumatoid Arthritis","enrollment":300},{"nctId":"NCT07352566","phase":"PHASE4","title":"Utilization of a Microdevice for Psoriasis and Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-01-01","conditions":"Psoriasis, Atopic Dermatitis","enrollment":10},{"nctId":"NCT07344428","phase":"NA","title":"Efficacy and Safety of CDED With Anti-TNF-α Biologics in Crohn's Disease: A Randomized Trial","status":"NOT_YET_RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2026-02-01","conditions":"Crohn's Disease；Mucosal Healing；Dietary Intervention","enrollment":185},{"nctId":"NCT02586831","phase":"PHASE1, PHASE2","title":"Diabetes Islet Preservation Immune Treatment","status":"WITHDRAWN","sponsor":"Camillo Ricordi and Jay Skyler","startDate":"2024-06-01","conditions":"Diabetes Mellitus, Type 1, Hypoglycemia, Autoimmune Diseases","enrollment":""},{"nctId":"NCT07258641","phase":"PHASE1, PHASE2","title":"Fluorescence Imaging of Adalimumab-680LT and Risankizumab-800CW in Inflammatory Bowel Disease","status":"NOT_YET_RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2026-01-15","conditions":"Ulcerative Colitis (UC), Crohn Disease (CD)","enrollment":30},{"nctId":"NCT05814627","phase":"PHASE3","title":"Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2023-06-15","conditions":"Rheumatoid Arthritis","enrollment":487},{"nctId":"NCT05633771","phase":"","title":"Observational Study, to Assess Treatment Retention of an Adalimumab Biosimilar (Hyrimoz®) in IBD Patients in Real Life Setting","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sandoz","startDate":"2023-02-16","conditions":"Inflammatory Bowel Disease","enrollment":562},{"nctId":"NCT06528431","phase":"PHASE4","title":"Design and Evaluation of an Individualized Biodrug Tapering Strategy Based on Biodrug Dosage: the MONITORA Study","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2024-12-19","conditions":"Arthritis, Rheumatoid","enrollment":180},{"nctId":"NCT01382160","phase":"PHASE4","title":"Serum Concentration of Adalimumab as a Predictive Factor of Clinical Outcomes in Rheumatoid Arthritis (AFORA)","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2011-01","conditions":"Rheumatoid Arthritis","enrollment":69},{"nctId":"NCT01895764","phase":"PHASE4","title":"Effect of the Combination of Methotrexate and Adalimumab on Reduction of Immunization in Ankylosing Spondylitis (COMARIS)","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2013-03-20","conditions":"Ankylosing Spondylitis","enrollment":110},{"nctId":"NCT05590455","phase":"PHASE2","title":"Tnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis","status":"RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2023-04-11","conditions":"Tuberculous Meningitis, HIV I Infection","enrollment":130},{"nctId":"NCT07221890","phase":"NA","title":"A Trial of Academic Detailing to Promote Prescribing of Biosimilars","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2025-11-06","conditions":"Autoimmune Diseases, Rheumatoid Arthritis (RA), Inflammatory Bowel Disease (IBD)","enrollment":1325},{"nctId":"NCT07268534","phase":"PHASE2","title":"Biologics in Folliculitis Decalvans : an Adaptative Trial Research","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-04-01","conditions":"Folliculitis Decalvans (FD)","enrollment":120},{"nctId":"NCT06180382","phase":"PHASE4","title":"Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration.","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2024-10-31","conditions":"Crohn's Disease","enrollment":220},{"nctId":"NCT03739853","phase":"PHASE4","title":"Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2019-05-14","conditions":"Psoriatic Arthritis","enrollment":192},{"nctId":"NCT03651518","phase":"PHASE2","title":"Personalized Therapies in Inflammatory Complex Disease","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-10-20","conditions":"Inflammatory Disease, Autoimmune Diseases","enrollment":32},{"nctId":"NCT02829424","phase":"PHASE4","title":"Multicenter Randomized Double Blind Controlled-study to Assess the Potential of Methotrexate Versus Placebo to Improve and Maintain Response to Anti TNF- Alpha Agents in Adult Patients With Moderate to Severe Psoriasis","status":"TERMINATED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2017-01-23","conditions":"Psoriasis","enrollment":78},{"nctId":"NCT05394805","phase":"","title":"A Study of Subcutaneous HUMIRA (Adalimumab) Injection to Assess Adverse Events and Change in Disease Activity In Adult Participants With Moderate to Severe Active Crohn's Disease (CD)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2022-06-29","conditions":"Crohn's Disease","enrollment":156},{"nctId":"NCT05535738","phase":"PHASE2, PHASE3","title":"Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation","status":"RECRUITING","sponsor":"Wei-Che Ko","startDate":"2022-11-15","conditions":"Skin Inflammation, Allergic Contact Dermatitis","enrollment":45},{"nctId":"NCT04978584","phase":"PHASE2","title":"Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-03-03","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":62},{"nctId":"NCT02632175","phase":"PHASE3","title":"Long-term Safety and Efficacy Study of Adalimumab in Pediatric Subjects With Ulcerative Colitis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-11-26","conditions":"Ulcerative Colitis","enrollment":59},{"nctId":"NCT06257875","phase":"PHASE2","title":"A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2024-03-23","conditions":"Ulcerative Colitis","enrollment":156},{"nctId":"NCT07208539","phase":"PHASE2","title":"AG Followed by FOLFIRINOX Both Combined With PD-L1 Antibodies as a Conversion Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-10-10","conditions":"Pancreatic Cancer","enrollment":77},{"nctId":"NCT05379322","phase":"PHASE3","title":"The Use of Synovial Biopsies in Predicting Response to Biologic Therapy in Rheumatoid Arthritis Patients","status":"WITHDRAWN","sponsor":"Abu Dhabi Stem Cells Center","startDate":"2023-03-01","conditions":"Rheumatoid Arthritis","enrollment":""},{"nctId":"NCT07181694","phase":"PHASE1","title":"A Study of Pharmacokinetics, Safety, and Immunogenicity of BCD-057 100 mg/mL, BCD-057 50 mg/mL, and Humira 100 mg/mL in Healthy Subjects","status":"RECRUITING","sponsor":"Biocad","startDate":"2025-03-12","conditions":"Healthy Adult Male","enrollment":444},{"nctId":"NCT07151937","phase":"PHASE2","title":"A Study of LAD191 in Adults With Hidradenitis Suppurativa","status":"NOT_YET_RECRUITING","sponsor":"Almirall, S.A.","startDate":"2025-09","conditions":"Hidradenitis Suppurativa","enrollment":200},{"nctId":"NCT05781152","phase":"PHASE4","title":"Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease","status":"RECRUITING","sponsor":"Connecticut Children's Medical Center","startDate":"2023-06-10","conditions":"Crohn Disease","enrollment":900},{"nctId":"NCT03104400","phase":"PHASE3","title":"A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-04-27","conditions":"Psoriatic Arthritis","enrollment":1705},{"nctId":"NCT02929251","phase":"PHASE2","title":"Randomized Trial Comparing Efficacy of Adalimumab, Anakinra and Tocilizumab in Non-infectious Refractory Uveitis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-06-29","conditions":"Uveitis, Biotherapy","enrollment":112},{"nctId":"NCT04447716","phase":"PHASE1","title":"An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2020-10-16","conditions":"Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma","enrollment":4},{"nctId":"NCT01385826","phase":"PHASE2, PHASE3","title":"Effect of Adalimumab for the Treatment of Uveitis in Juvenile Idiopathic Arthritis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2011-06-29","conditions":"Uveitis, Juvenile Arthritis","enrollment":34},{"nctId":"NCT06673134","phase":"","title":"Prospective Cohort Establishment and Clinical Observation of Children With Crohn's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tongji Hospital","startDate":"2023-12-01","conditions":"Crohn Disease","enrollment":100},{"nctId":"NCT07152977","phase":"","title":"Description of the Radiological Response of Anoperineal Fistulizing Lesions of Crohn's Disease","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2019-07-31","conditions":"Anoperineal Lesions, Crohn&#39;s Disease Relapse","enrollment":52},{"nctId":"NCT07149792","phase":"PHASE4","title":"A Multi-center RCT Clinical Trial on Personalized Precision Medicine for Patients With Psoriasis and Psoriatic Arthritis and Investigation on Cardiovascular Biomarkers","status":"RECRUITING","sponsor":"Taichung Veterans General Hospital","startDate":"2025-07-29","conditions":"Psoriasis, Psoriasis Arthritis, Biologics","enrollment":50},{"nctId":"NCT07140666","phase":"","title":"Analysis of Influence Factors on Osteopenia in Different Treatment of Psoriasis","status":"COMPLETED","sponsor":"Chongli Yu","startDate":"2022-08-01","conditions":"Psoriasis","enrollment":100},{"nctId":"NCT07138898","phase":"PHASE2","title":"Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-09","conditions":"Rheumatic Disease","enrollment":80},{"nctId":"NCT07137858","phase":"PHASE2","title":"Adebrelimab Combined With Carboplatin and Albumin-bound Taxanol in the Treatment of Resectable Locally Advanced Oral Squamous Cell Carcinoma Cardiac, Randomized, Phase II Exploratory Study","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-08-15","conditions":"Oral Squamous Cell Carcinoma (OSCC), Neoadjuvant Chemoimmunotherapy","enrollment":70},{"nctId":"NCT07128472","phase":"NA","title":"Evaluation of IL 12B Genetic Polymorphism (rs3213094)","status":"RECRUITING","sponsor":"South Valley University","startDate":"2025-08-01","conditions":"Psoriasis","enrollment":40},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT03938701","phase":"PHASE2","title":"Fluorescence Imaging of IBD and RA Using Adalimumab-800CW","status":"RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2024-08-06","conditions":"IBD, Rheumatoid Arthritis","enrollment":36},{"nctId":"NCT06729463","phase":"NA","title":"IKBKB Gene Polymorphism (Single Nucleotide Polymorphism) (SNP) in Psoriatic and Psoriatic Arthritis Patients","status":"COMPLETED","sponsor":"South Valley University","startDate":"2024-12-01","conditions":"Psoriasis, Psoriatic Arthritis","enrollment":50},{"nctId":"NCT03316781","phase":"PHASE3","title":"Study of Efficacy and Safety of HLX03 in Subjects With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Shanghai Henlius Biotech","startDate":"2017-10-27","conditions":"Plaque Psoriasis","enrollment":262},{"nctId":"NCT07113834","phase":"","title":"Characteristics of Ankylosing Spondylitis Associated Uveitis","status":"COMPLETED","sponsor":"Benha University","startDate":"2023-09-01","conditions":"Uveitis","enrollment":22},{"nctId":"NCT04997733","phase":"PHASE3","title":"Fecal Microbiota Transplantation in Crohn's Disease as Relay After Anti-TNF Withdrawal","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-09-22","conditions":"Crohn Disease","enrollment":150},{"nctId":"NCT04985435","phase":"PHASE4","title":"Better After CHoosing. Randomly Allocated or Patient Preference Based Treatment With Filgotinib or TNFi in RA (BACH)","status":"RECRUITING","sponsor":"R.Bos","startDate":"2021-05-12","conditions":"Rheumatoid Arthritis","enrollment":100},{"nctId":"NCT03414502","phase":"PHASE3","title":"Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response","status":"RECRUITING","sponsor":"University of Nebraska","startDate":"2007-12-10","conditions":"Rheumatoid Arthritis","enrollment":400},{"nctId":"NCT04891640","phase":"NA","title":"Biologic Abatement and Capturing Kids' Outcomes and Flare Frequency in Juvenile Spondyloarthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital of Philadelphia","startDate":"2021-11-11","conditions":"Juvenile Spondyloarthritis","enrollment":164},{"nctId":"NCT02629159","phase":"PHASE3","title":"A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2015-12-01","conditions":"Rheumatoid Arthritis","enrollment":1629},{"nctId":"NCT07093827","phase":"","title":"A Prospective Cohort Study on the Effect of Spinal Spinal Cord Injury on Sexual Function in Male Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2020-01-01","conditions":"Sexual Function Abnormal, Spinal Cord Injuries (SCI)","enrollment":1600},{"nctId":"NCT03915964","phase":"PHASE4","title":"A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-04-25","conditions":"Rheumatoid Arthritis","enrollment":2663},{"nctId":"NCT04086745","phase":"PHASE4","title":"A Study of Baricitinib in Participants With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-02-14","conditions":"Rheumatoid Arthritis","enrollment":1317},{"nctId":"NCT04750213","phase":"","title":"A Study to Assess Adverse Events and Change in Disease State in Adult Participants Being Treated With Humira in Participants Diagnosed With Pyoderma Gangrenosum (PG)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2021-02-12","conditions":"Pyoderma Gangrenosum","enrollment":60},{"nctId":"NCT02130362","phase":"","title":"A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2014-08-28","conditions":"Crohn's Disease","enrollment":1446},{"nctId":"NCT01848561","phase":"","title":"A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2013-04-29","conditions":"Ulcerative Colitis (UC)","enrollment":8250},{"nctId":"NCT06390436","phase":"PHASE4","title":"Therapeutic Drug Monitoring-baSed adalimuMab De-escalatiOn in nOn-infecTious cHronic Uveitis","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2025-06","conditions":"Uveitis, Chronic Disease","enrollment":320},{"nctId":"NCT07041112","phase":"","title":"Ten-Year Biologic Drug Survival in Psoriasis: Role of Genetic and Cardiometabolic Predictors","status":"COMPLETED","sponsor":"Juan Ruano Ruiz","startDate":"2012-01-01","conditions":"Psoriasis, Psoriatic Arthritis (PsA), Cardiovascular Risk Factors","enrollment":1000},{"nctId":"NCT06640517","phase":"PHASE3","title":"Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children With Moderate to Severe Plaque Psoriasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biocad","startDate":"2024-08-08","conditions":"Plaque Psoriasis","enrollment":140},{"nctId":"NCT05928039","phase":"PHASE4","title":"PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease","status":"RECRUITING","sponsor":"University of Calgary","startDate":"2023-10-25","conditions":"Crohn Disease","enrollment":297},{"nctId":"NCT07013838","phase":"PHASE4","title":"The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis","status":"NOT_YET_RECRUITING","sponsor":"Chinese SLE Treatment And Research Group","startDate":"2025-06-15","conditions":"Takayasu Arteritis (TAK)","enrollment":50},{"nctId":"NCT05414201","phase":"PHASE4","title":"A Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Participants Requiring High Dose Corticosteroids for Active Non-Infectious Intermediate, Posterior, or Pan-Uveitis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2022-07-07","conditions":"Non-infectious Intermediate Posterior- or Pan-uveitis","enrollment":87},{"nctId":"NCT05108259","phase":"PHASE1","title":"To Compare the Pharmacokinetics and Safety of PBP1502 and Humira in Healthy Subjects","status":"RECRUITING","sponsor":"Prestige Biopharma Limited","startDate":"2022-03-30","conditions":"Healthy Volunteers","enrollment":324},{"nctId":"NCT03011268","phase":"NA","title":"Anti-tumor Necrosis Factor in Patients With Ulcerative Colitis in Clinical Remission: to Continue or Not?","status":"COMPLETED","sponsor":"Helse Møre og Romsdal HF","startDate":"2017-06-09","conditions":"Colitis,Ulcerative","enrollment":174},{"nctId":"NCT05040464","phase":"PHASE3","title":"Comparison of Azathioprine to Methotrexate in Combination Therapy With Adalimumab in Crohn's Disease: an Open-label Randomized Controlled Trial","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2021-08-26","conditions":"Crohn Disease, Azathioprine, Methotrexate","enrollment":166}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":47,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AMJEVITA™","Adalimumab-atto"],"phase":"phase_3","status":"active","brandName":"ABP 501","genericName":"ABP 501","companyName":"Amgen","companyId":"amgen","modality":"Biologic","firstApprovalDate":"","aiSummary":"ABP 501 is a biosimilar of adalimumab that blocks tumor necrosis factor-alpha (TNF-α) to reduce inflammation. Used for Rheumatoid arthritis, Crohn's disease, Ulcerative colitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}